Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CBLI $4.21 0.5000 +13.48%
ADXS $10.14 0.9800 +10.70%
ZIOP $9.08 0.6400 +7.58%
APRI $1.43 0.1000 +7.52%
IMMU $5.28 0.3500 +7.10%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

XNCR $15.53 -1.3900 -8.22%
TLOG $5.00 -0.2500 -4.76%
EXEL $1.97 -0.0700 -3.43%
NLNK $37.79 -1.1700 -3.00%
FPRX $26.20 -0.8100 -3.00%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Rocky Mountain Cancer Centers Enhances Services in South Denver, Adding Two New Medical Oncologists and Greenwood Village Treatment Center

(The US Oncology Network) Jan 12, 2015 - Breast cancer specialist Dr. Robin Kovachy rejoins RMCC; Dr. Lillian Klancar brings general oncology and hematology, lung and breast cancer expertise.
read corporate press release 

Mersana Therapeutics and Takeda Expand Antibody-Drug Conjugate Partnership

(Mersana) Jan 12, 2015 - Mersana Therapeutics, Inc. announced today that they have expanded their ongoing collaboration with Takeda Pharmaceutical Company Limited to create novel Fleximer® antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets.
read corporate press release 

Personal Genome Diagnostics, Inc. and Human Longevity, Inc. Sign Cancer Genomics Agreement

(Human Longevity) Jan 12, 2015 – Personal Genome Diagnostics, Inc. and Human Longevity, Inc. today announced that HLI will have access to PGDx’s cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelectTM, PlasmaSelectTM, CancerXomeTM, METDetect™ and CancerComplete™.
read corporate press release 

Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients

(CNNMoney) Jan 12, 2015 - Biocept, Inc. today announced the launch of its EGFR mutation test that targets a region of the gene that includes T790M, a biomarker that identifies therapy-resistant tumors utilizing its proprietary Selector technology.
read article 

Tokai Pharmaceuticals Provides Companion Diagnostic Update

(StreetInsider) Jan 12, 2015 - Tokai Pharmaceuticals, Inc., today announced that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company’s lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.
read article 

Genomic Health Plans Line of Liquid-Biopsy Tests for Cancer

(Wall Street Journal) Jan 11, 2015 - Genomic Health Inc. plans to develop a line of liquid biopsy tests that can detect genetic evidence of cancer in a vial of blood.
read article (paid subscription required) 

Britain's Health Service to Halt Access to Some Costly Cancer Drugs

(Reuters) Jan 12, 2015 - Several expensive cancer medicines will no longer be available on Britain's state-funded National Health Service (NHS) following an overhaul of an over-budget drug funding scheme, NHS England said on Monday.
read article  

AZ Pulls Lynparza's Application for CDF Funding

(PharmaTimes [UK]) Jan 12, 2015 - AstraZeneca has withdrawn an application to get its first-in-class ovarian cancer therapy Lynparza (olaparib) funded by the Cancer Drugs Fund in England.
read article 

OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer

(MarketWatch) Jan 12, 2015 - OncoSec Medical Inc. plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer (TNBC).
read article 

Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

(NASDAQ) Jan 12, 2015 - Seattle Genetics, Inc. and Bristol-Myers Squibb Company today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.
read article 

Singapore Researchers Discover New Therapeutic Target for Treatment of Acute Myeloid Leukaemia

(NUS [Singapore]) Jan 12, 2015 - A study by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has found new interactions between two molecules involved in acute myeloid leukaemia (AML), STAT3 and PRL-3, which may offer a new therapeutic target for cancer treatment.
read press release 

Potentially Targetable Signaling Pathway Generates Slowly Proliferating, Chemo-resistant Cancer Cells

(AACR) Jan 12, 2015 - A signaling pathway responsible for the generation of slowly proliferating cancer cells, which are hard to eradicate with current treatments and thought to be a cause of subsequent disease relapse, has been reported in a Rapid Impact study published in Molecular Cancer Research, a journal of the American Association for Cancer Research.
read press release 

Mayo Researchers Find Cancer Biopsies Do Not Promote Cancer Spread

(Mayo Clinic) Jan 9, 2015 - A study of more than 2,000 patients by researchers at Mayo Clinic's campus in Jacksonville, Florida, has dispelled the myth that cancer biopsies cause cancer to spread.
read press release 

Secondary Analysis of RTOG 0247 Demonstrates Favorable OS Rates for Rectal Cancer Patients

(ASTRO) Jan 9, 2015 - Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, respectively, according to a new study.
read press release 

Study: Cancer Survivors Struggle Post Treatment

(University of Central Florida blog) Jan 12, 2015 - Even decades after being cured, many cancer survivors face physical and mental challenges resulting from their disease and its treatment.
read article 

Warning: That Tan Could Be Hazardous

(New York Times) Jan 10, 2015 - Tanning salons dot strip malls across the country, promising prettiness and, in some cases, better health, despite a growing body of evidence that links indoor tanning to skin cancer.
read article 

Merck Accelerates Drug-Submission Plans

(Wall Street Journal) Jan 11, 2015 - Merck & Co. has accelerated its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in a bid to close the gap with competitors in two lucrative segments.
read article (paid subscription required) 

Roche to Buy Majority Stake in Foundation Medicine, Leader in Tumor Testing

(New York Times/DealBook) Jan 12, 2015 - The Swiss pharmaceutical giant Roche will pay more than $1 billion in a deal aimed at improving both cancer treatment and drug development.
read article 

The Coming Wave of New Cancer Fighting Drugs

(Bloomberg) Jan 10, 2015 - The hottest area in cancer drugs is going mainstream this year.
read article 

Bristol-Myers' Stock Jumps on Lung-cancer Drug Success

(BloombergBusinessweek/Associated Press) Jan 12, 2015 - Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer.
read article 

CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early

(Bristol-Myers Squibb) Jan 11, 2015 - Opdivo demonstrates superior overall survival in this Phase 3 trial.
read corporate press release 

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

(TheStreet) Jan 12, 2015 - Foundation Medicine will become majority-owned by Roche as part of a $1 billion-plus strategic partnership to expand the use of genetic testing in cancer drug research and treatment, the companies announced today.
read article 

The Cancer Drugs Patients Are to Be Denied on NHS

(The Telegraph [UK]) Jan 12, 2015 - Here are eight drugs among those expected to be “delisted” so that they are not routinely funded by the NHS.
read article 

BMS' Opdivo Set For Early Access in UK

(PMLiVE) Jan 8, 2015 - Bristol-Myers Squibb could see an early launch of its new melanoma therapy Opdivo in the UK after becoming the first drug of its class given a new fast-track status by the country's drugs regulator.
read article 

Helsinn and Pharmacosmos Enter Into an Exclusive License Agreement For the Development and Commercialization of Monofer® in US

(CNBC) Jan 8, 2015 - Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer®, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia.
read article